SAREPTA THERAPEUTICS INC's ticker is SRPT and the CUSIP is 803607100. A total of 367 filers reported holding SAREPTA THERAPEUTICS INC in Q1 2020. The put-call ratio across all filers is 1.30 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $14,866,784 | +5.9% | 122,643 | 0.0% | 0.27% | +12.7% |
| Q2 2023 | $14,045,076 | -45.6% | 122,643 | -34.5% | 0.24% | -50.0% |
| Q1 2023 | $25,811,148 | -50.3% | 187,268 | -73.1% | 0.47% | -38.4% |
| Q1 2021 | $51,959,000 | -67.3% | 697,156 | -25.2% | 0.77% | -68.4% |
| Q4 2020 | $158,813,000 | +21.4% | 931,512 | 0.0% | 2.44% | -4.9% |
| Q3 2020 | $130,812,000 | -18.1% | 931,512 | -6.5% | 2.56% | -26.2% |
| Q2 2020 | $159,699,000 | +63.9% | 996,000 | 0.0% | 3.47% | +10.0% |
| Q1 2020 | $97,429,000 | -24.2% | 996,000 | 0.0% | 3.16% | -12.9% |
| Q4 2019 | $128,524,000 | +40.0% | 996,000 | -18.3% | 3.62% | +19.3% |
| Q3 2019 | $91,815,000 | -46.2% | 1,219,000 | +8.5% | 3.03% | -41.5% |
| Q2 2019 | $170,640,000 | +69.4% | 1,123,000 | +32.9% | 5.19% | +49.7% |
| Q1 2019 | $100,736,000 | +9.2% | 845,168 | 0.0% | 3.47% | -15.1% |
| Q4 2018 | $92,233,000 | -7.9% | 845,168 | +36.3% | 4.08% | +11.0% |
| Q3 2018 | $100,136,000 | +102.0% | 620,000 | +65.3% | 3.68% | +78.8% |
| Q2 2018 | $49,568,000 | +196.0% | 375,000 | +65.9% | 2.06% | +162.4% |
| Q1 2018 | $16,744,000 | +86.9% | 226,000 | +40.4% | 0.78% | +67.9% |
| Q4 2017 | $8,958,000 | +22.7% | 161,000 | 0.0% | 0.47% | +12.8% |
| Q3 2017 | $7,303,000 | +12.6% | 161,000 | -51.5% | 0.41% | +14.4% |
| Q1 2016 | $6,486,000 | -49.4% | 332,300 | 0.0% | 0.36% | -43.5% |
| Q4 2015 | $12,820,000 | +22.3% | 332,300 | +1.8% | 0.64% | +5.3% |
| Q3 2015 | $10,481,000 | +32.9% | 326,400 | +26.0% | 0.61% | +42.6% |
| Q2 2015 | $7,884,000 | +129.1% | 259,100 | 0.0% | 0.43% | +64.9% |
| Q1 2015 | $3,441,000 | -8.2% | 259,100 | 0.0% | 0.26% | -36.7% |
| Q4 2014 | $3,749,000 | -31.4% | 259,100 | 0.0% | 0.41% | -46.4% |
| Q3 2014 | $5,467,000 | -29.2% | 259,100 | 0.0% | 0.76% | -27.3% |
| Q2 2014 | $7,719,000 | +24.0% | 259,100 | 0.0% | 1.05% | +8.6% |
| Q1 2014 | $6,226,000 | +115.6% | 259,100 | +82.7% | 0.97% | +8.7% |
| Q4 2013 | $2,888,000 | – | 141,800 | – | 0.89% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Perceptive Advisors | 2,878,979 | $69,182,000 | 7.27% |
| Eventide Asset Management | 259,100 | $6,226,000 | 0.97% |
| GLADE BROOK CAPITAL PARTNERS LLC | 251,000 | $6,032,000 | 0.93% |
| IMS Capital Management | 32,215 | $774,000 | 0.91% |
| Perceptive Advisors | 350,000 | $8,413,000 | 0.88% |
| Benchmark Capital Advisors | 34,900 | $839,000 | 0.58% |
| BECK CAPITAL MANAGEMENT, LLC | 24,744 | $636,000 | 0.49% |
| SABBY MANAGEMENT, LLC | 352,100 | $8,461,000 | 0.47% |
| Hatteras Alternative Mutual Funds, LLC | 39,404 | $947,000 | 0.46% |
| Potomac Capital Management, Inc. | 22,100 | $531,000 | 0.45% |